Last updated: February 22, 2026
What is the drug associated with NDC 82009-0080?
NDC 82009-0080 corresponds to EpiPen (epinephrine injection, auto-injector). EpiPen is used for emergency treatment of anaphylaxis caused by allergic reactions.
Market Size and Key Players
Market Size
The global epinephrine auto-injector market was valued at approximately $2.3 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of about 8% from 2023 to 2030 due to increasing allergy prevalence.
Major Competitors
- Mylan (Mylan EpiPen and authorized generics)
- Pfizer (EpiPen, acquired by Mylan)
- Teva Pharmaceuticals (Adrenaclick)
- SAI (Auvi-Q)
- Impax Laboratories (Adavailable)
Market Shares
| Company |
Market Share (2022) |
Product Offerings |
| Mylan (Pfizer) |
60-65% |
EpiPen (brand), authorized generics |
| Teva |
15-20% |
Adrenaclick |
| Others |
15-20% |
Auvi-Q, Adavailable |
Pricing Trends and Projections
Current Pricing (As of 2023)
| Product |
List Price |
Average Actual Transaction Price (Patent Years) |
Notes |
| EpiPen (original) |
$600-$700 |
$300-$350 per two-pack |
Prices surged in 2016-2017. |
| Authorized Generic (Mylan) |
$300-$350 |
Similar to brand, slightly lower |
Launched after patent expiry in 2018. |
| Auvi-Q |
$400-$500 |
$200-$350 |
Marketed as an alternative; fluctuates in pricing. |
Price Projections (Next 5 Years)
- 2023-2024: Prices are expected to remain stable due to market competition, with minor declines as generic availability increases.
- 2025-2026: Introduction of new generics and biosimilars could reduce prices further, with estimates down to $150-$200 per two-pack.
- 2027-2028: Continued competition may push prices below $150 per two-pack, especially with direct-to-consumer and pharmacy channels increasing access.
Factors Influencing Price
- Patent expirations (e.g., Mylan’s authorized generic in 2018)
- Entry of biosimilar competitors
- Changes in prescribing policies or reimbursement frameworks
- Manufacturer margin adjustments
Regulatory Factors
- The FDA has approved multiple generic formulations, increasing market competition.
- Patent challenges have facilitated generic entry post-2018.
- State and federal legislation, including insurance mandates for generics, influence pricing.
Future Market Drivers
- Rising prevalence of allergic conditions globally.
- Increased awareness and emergency preparedness.
- Potential new formulations or delivery systems, such as needle-free injectors.
- Expansion of access via telehealth and pharmacy distribution.
Key Challenges
- Price elasticity of demand for emergency medication.
- Limited substitution options once an emergency arises.
- Price transparency issues in the supply chain.
- Patent litigation delays for new entrants.
Conclusion
The market for NDC 82009-0080 (EpiPen) and equivalent products shows a trend toward lower prices driven by generic competition and market saturation. Over the next five years, prices are projected to decline steadily, with significant reductions possible by 2027. Market share consolidation remains centered around Mylan’s generics, with new competitors likely to further compress prices.
Key Takeaways
- The embedded market size exceeds $2 billion, with high growth driven by allergy prevalence.
- Prices for branded EpiPen peaked near $700 per two-pack but are expected to fall below $150 in five years due to generics.
- Market competition, patent expiry, and biosimilar entry will shape pricing trajectories.
- Access and affordability improvements are likely as generics gain wider adoption.
FAQs
-
What is the primary driver behind EpiPen price fluctuations?
Patent expirations and subsequent generic competition lead to significant price reductions.
-
How does the introduction of biosimilars affect the market?
Biosimilars increase supply options and drive down prices through competitive pressure.
-
Are there alternatives to EpiPen with different price points?
Yes, products like Auvi-Q and Adrenaclick offer lower-cost options, with prices often below $200 per two-pack.
-
What factors could prevent further price decreases?
Market monopolies, supply chain disruptions, and regulatory delays in approving new generics.
-
How might healthcare policy influence future prices?
Increased emphasis on drug affordability and preferred formulary placements may further lower prices.
References
[1] Global Market Insights. (2022). Epinephrine Auto-Injectors Market Size and Forecast.
[2] IQVIA. (2023). Pharmaceutical Market Trends Report.
[3] U.S. Food and Drug Administration. (2022). Approvals and Patent Status of Generic Epinephrine Auto-injectors.
[4] MarketWatch. (2023). Epinephrine Auto-Injector Price Trends.
[5] Congressional Research Service. (2022). Drug Patent Litigation and Market Entry.
